Latest news with #pediatriccancer
Yahoo
2 days ago
- Business
- Yahoo
Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025
BRISBANE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) ('Day One' or the 'Company'), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, August 5, 2025 at 4:30 p.m. ET to report financial results and discuss corporate progress for the second quarter 2025. Live audio of the webcast will be accessible on Day One's Events on the Day One Media & Investors page. An archived version of the webcast will be available for replay on the News & Events section of the Day One Media & Investors page for 30 days following the event. About Day One Biopharmaceuticals Day One Biopharmaceuticals believes when it comes to pediatric cancer, we can do better. The Company was founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. Inspired by 'The Day One Talk' that physicians have with patients and their families about an initial cancer diagnosis and treatment, Day One aims to re-envision cancer drug development and redefine what's possible for all people living with cancer – regardless of age – starting from day one. Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important targeted cancer treatments. The Company's pipeline includes tovorafenib (OJEMDA™) and DAY301. Day One is based in Brisbane, California. For more information, please visit or find the Company on LinkedIn or X. Day One uses its Investor Relations website ( its X handle ( and LinkedIn Home Page ( as a means of disseminating or providing notification of, among other things, news or announcements regarding its business or financial performance, investor events, press releases, and earnings releases, and as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. DAY ONE MEDIALaura Cooper, Head of Communicationsmedia@ DAY ONE INVESTORSLifeSci Advisors, PJ Kelleherpkelleher@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-07-2025
- Business
- Yahoo
Denny's Teams Up with Cookies for Kids' Cancer to ‘Strike Out' Pediatric Cancer
America's Diner launches national partnership to help fund breakthrough cancer research, donating proceeds from Kids' menu and limited-edition T-shirt Denny's and Cookies for Kid's Cancer team up to raise funds for pediatric cancer research. Denny's and Cookies for Kid's Cancer team up to raise funds for pediatric cancer research. Spartanburg, SC, July 16, 2025 (GLOBE NEWSWIRE) -- Denny's is adding to their partnership with Cookies for Kids' Cancer, a leading nonprofit organization committed to raising funds for pediatric cancer, with a new way that everyone can help. For 16 years, Denny's has supported Cookies for Kids' Cancer on a regional level, raising nearly $1.5 million to fund research for new, improved treatments. The expanded nationwide partnership will drive progress for kids who deserve 'More time, more options, and a future beyond cancer.' In true Grand Slam® fashion, Denny's has launched a limited-edition 'Let's Strikeout Kids' Cancer' T-shirt, available now at All proceeds from the shirt sales will benefit Cookies for Kids' Cancer. In addition, Denny's is supporting the cause through its menu: for every Kids' menu item sold now through Spring of 2026, a portion of the proceeds will be donated to help fight pediatric cancer. And lastly, guests can also contribute by rounding up their checks to support fundraising efforts now through August 26, 2025. 'At our core, we love to feed people and serve families in our communities, which includes those directly impacted by pediatric cancer. A diagnosis can happen to any family at any time. I know this too well, as I lost my brother to cancer at a young age,' said Chris Bode, president and chief operating officer of Denny's. 'There's still so much work to be done to find a cure. Together with Cookies for Kids' Cancer, we will fund meaningful progress and get one step closer to ending the disease once and for all.' 'With Denny's nationwide presence, we can raise critical awareness and funds for pediatric cancer, the leading cause of death by disease in children. Denny's guests likely know a child affected, and the concept of being a 'Good Cookie' is something we think every Denny's guest can embrace,' said Gretchen Witt, co-founder and executive director. 'Our collaboration will directly boost the number of research grants we can fund, which lead to new treatment options and real hope for families. In fact, the very first treatment we helped to fund became available seven months after my son Liam lost his battle and has since helped countless kids.' Guests looking to support Cookies for Kids' Cancer can head to their local Denny's, as every visit helps. Guests can also grab their very own 'Let's Strikeout Kids' Cancer' T-shirt *while supplies last at To learn more, visit ### About Denny's Corp Denny's is a Spartanburg, S.C. - based family dining restaurant brand that has been welcoming guests to our booths for more than 70 years. Our guiding principle is simple: We love to feed people. Denny's provides craveable meals at a meaningful value across breakfast, lunch, dinner, and late night. Whether it's at our brick-and-mortar locations, via Denny's on Demand (the first delivery platform in the family dining segment), or at The Meltdown, Banda Burrito, and The Burger Den, our three virtual restaurant concepts, Denny's is ready to delight guests whenever and however they want to order. Our longstanding commitment to supporting our local communities in need is brought to life with our Mobile Relief Diner (that delivers hot meals to our neighbors during times of disaster), Denny's Hungry for Education™ scholarship program, our annual fundraiser with long-time-partner No Kid Hungry, and our new partnership supporting Cookies for Kids' Cancer in their mission to fund research for new, improved and less toxic treatments for kids facing cancer. Denny's is one of the largest franchised full-service restaurant brands in the world, based on the number of restaurants. As of March 26, 2025, the Denny's brand consisted of 1,491 restaurants, 1,430 of which were franchised and licensed restaurants and 61 of which were company-operated. This includes 166 restaurants in Canada, Costa Rica, Curacao, El Salvador, Guam, Guatemala, Honduras, Indonesia, Mexico, New Zealand, the Philippines, Puerto Rico, the United Arab Emirates, and the United Kingdom. To learn more about Denny's, please visit our brand website at or the brand's social channels via Facebook, Instagram, LinkedIn or YouTube. About Cookies for Kids' CancerCookies for Kids' Cancer is a nationally recognized 501(c)(3) nonprofit organization dedicated to funding research for new, improved and less toxic treatments for pediatric cancer—the #1 disease killer of children in the U.S. Inspired by the belief that everyone can make a difference, the organization mobilizes individuals, businesses, and communities to raise critical funding through grassroots events like bake sales, fitness challenges, and corporate campaigns. Since its founding, Cookies for Kids' Cancer has granted more than $23 million, supporting over 140 cutting-edge research projects and contributing to 60 new treatment options. Backed by a global network of 18,000+ passionate supporters, every dollar donated is tax-deductible and fuels hope for children fighting cancer. Attachments Denny's and Cookies for Kid's Cancer team up to raise funds for pediatric cancer research. Denny's and Cookies for Kid's Cancer team up to raise funds for pediatric cancer research. CONTACT: Denny's Media Team Denny's 864-597-8005 media@
Al Arabiya
08-07-2025
- Business
- Al Arabiya
St. Jude Children's Hospital's fundraising arm selects new CEO in midst of global expansion
Ike Anand was promoted to president and chief executive officer of ALSAC, St. Jude Children's Research Hospital's fundraising organization, on Tuesday. The leadership change comes as ALSAC – which raised more than $2.5 billion for the Memphis-based hospital in 2024, according to tax filings – navigates a global expansion and an increasingly complicated funding landscape in the US. 'My role is to make sure that ALSAC is able to deliver on its promises to St. Jude so that St. Jude can continue to dream big,' said Anand, who has been ALSAC's chief operating officer since 2020. 'And ALSAC has a lot of initiatives in the pipeline to make sure that that happens.' Dr. Frederick M. Azar, chairman of ALSAC's board of directors, said Anand has been instrumental in redefining the organization's strategic direction, including its six-year, $12.9 billion plan to provide pediatric cancer cures and treatments globally, and will help it continue to grow. 'Throughout his tenure, Ike has demonstrated visionary leadership and an unwavering commitment to the St. Jude mission,' Azar said in a statement. For Anand, who spent 15 years at travel tech firm Expedia Group and the rest of his career at other for-profit businesses, heading a nonprofit – even one as large and influential as ALSAC – was not an early life goal. But the COVID-19 pandemic and its impact on his family and friends changed that. 'I was hunting to do something that makes me feel valuable and purpose-driven in this world,' Anand said. 'And what I found… it was the perfect match.' At Expedia, he learned the importance of data, nurturing customer relationships, and managing teams around the world – experiences he says help at ALSAC. 'We have a culture here now of testing and learning, getting better at what we do, and ultimately understanding that we're not really competing against anybody else,' he said. 'We are trying to be better at what we do.' One area where Anand has drawn attention is incorporating artificial intelligence into ALSAC's fundraising. Its initiative of using AI to help guide its communications with donors has influenced multiple programs in philanthropy. Anand is quick to point out that ALSAC does not use donors' specific data to communicate to them individually but does use aggregated data to make decisions about what information may interest certain types of donors. 'For us, it is really, really vital that the consumers have trust in us and that they see us valuing their privacy, that they see us valuing their information and using it in the right manner,' he said. 'And so we're really careful about it.' Health care policy changes from President Donald Trump's administration may impact rural hospitals and increase the need for St. Jude's services, which include free treatment for children with cancer. However, Anand says that St. Jude and ALSAC see it as their mission to care for all 400,000 children around the world diagnosed with cancer, so the changes do not really change their focus. 'Our mission is a unifying mission,' he said. 'We are not a political organization. I think everybody agrees that saving children is one of the most important things we can do as humanity.' Marlo Thomas, National Outreach Director for St. Jude and daughter of the late entertainer and philanthropist Danny Thomas, who founded ALSAC and St. Jude, said that goal has remained the same. 'When my father founded St. Jude with a dream that no child should die in the dawn of life, he meant no child anywhere,' she said in a statement. 'Ike Anand is the perfect person to carry that dream forward and help continue to expand our mission globally.'
Health Line
27-06-2025
- Health
- Health Line
Diffuse Intrinsic Pontine Glioma (DIPG)
This rare, aggressive type of cancerous tumor that forms in the brain stem often develops in childhood and is difficult to treat. A diffuse intrinsic pontine glioma (DIPG) is an aggressive type of cancerous tumor that forms in the brain stem. That's the area at the base of your brain that connects the brain to the spine. The brain stem controls most of your basic functions, including vision, hearing, talking, walking, eating, breathing, heart rate, and more. Gliomas are tumors that grow from glial cells, which are found throughout the nervous system. They surround and support nerve cells, called neurons. DIPG most often develops in children between the ages of 5 and 10. However, it can affect anyone at any age. The condition is rare — about 300 children are diagnosed with DIPG every year in the United States. It is also difficult to treat and has a negative outlook. How are these tumors graded? Most DIPG tumors are high grade, either grades 3 or 4. Very few are grade 2, and those that are act similarly to high grade tumors. Because DIPG tumors are located in such a sensitive area, a traditional biopsy of the tumor isn't always recommended. However, a stereotactic biopsy is an imaging technique that can provide pathology findings and guide treatment decisions. What are the symptoms? DIPG symptoms can vary depending on factors such as: the location of the tumor the size of the tumor whether or not the tumor has spread how fast the tumor grows the child's age and stage of development Symptoms may develop suddenly and include: eye movement issues vision problems trouble talking, chewing, or swallowing drooping on one side of the face nausea and vomiting a headache that develops in the morning or goes away after vomiting weakness in the limbs loss of balance trouble walking behavior changes issues with learning However, these symptoms could be a sign of other issues outside of DIPG, so it's important to consult your child's doctor to determine the underlying cause. What causes DIPG? The development of DIPG is associated with changes in the way glial cells grow and divide. However, the exact cause of the condition is unknown, and there are no known risk factors. Scientists have identified a few genetic mutations associated with DIPG, but more research is needed to better understand the origins of this condition. How's it diagnosed? If DIPG is suspected, your child's doctor will ask about your child's personal and family medical history. They will then do a physical and neurological exam. Your child's doctor may also run additional testing to help confirm a diagnosis of DIPG, such as: MRI scan: This type of imaging uses radio waves and a large magnetic field to create images of the inside of the body. An MRI can help distinguish between a tumor and typical tissue and swelling that might be related to the tumor. Stereotactic biopsy: This form of imaging may be used to provide information about the cancerous tumor and guide treatment decisions. Immunohistochemistry: This lab test uses antibodies to check for specific antigens in a tissue sample to help distinguish one type of cancer from another to make an accurate diagnosis. Sometimes, you may seek a second opinion to confirm your child's diagnosis and treatment approach. How's it treated? Your child's DIPG treatment plan will take factors into consideration, such as their overall health and whether the cancer is newly diagnosed or recurring. Treatment options may include: Steroids: These medications are often given at diagnosis in preparation for radiation therapy. Radiation therapy: This is the main treatment for DIPG. It involves using high-energy X-rays to kill cancer cells and shrink tumors. However, radiation is a temporary treatment and is not viewed as a cure for DIPG. Chemotherapy: This treatment uses powerful chemicals to destroy cancer cells and is sometimes used along with radiation therapy. However, this combination treatment is also not a permanent cure. Surgery: Surgical removal of tumors that are so close to the brain stem often isn't recommended. However, in children who have increased fluid around the brain or spinal cord, surgery can be used to place a shunt to carry fluid away from the brain and reduce pressure on the brain or spinal cord. Palliative care: Because there's no cure for DIPG, treatment often involves strategies to help improve quality of life for both you and your child. Clinical trials: Your child's doctor may recommend enrolling in a clinical trial to help advance the future of DIPG treatment. What's the outlook? A diagnosis of DIPG can be life-altering news. The condition is currently considered fatal. Even with treatment, nearly every case of DIPG starts to grow again within 6 to 12 months. At that point, no further treatment is known to help improve survival. The average survival is usually 9 months, and only 10% of children diagnosed with DIPG live for more than 2 years. Researchers are trying to learn as much as they can about DIPG in hopes of unlocking a lasting treatment. They are also studying how to prevent these cancerous tumors from developing in children with the genetic mutations associated with them. Various clinical trials are currently underway. To learn more about ongoing or upcoming DIPG clinic trials, you can visit
Yahoo
24-06-2025
- Business
- Yahoo
OS Therapies Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma
Company has requested End of Phase 2 Meeting and Breakthrough Therapy Designation (BTD) based upon the positive FDA Meeting feedback NEW YORK, June 24, 2025--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that it received positive written feedback from the US Food & Drug Administration ("FDA") Type D Meeting that occurred in mid-June 2025 regarding endpoints required to support an Accelerated Approval Program marketing application for its Phase 2b trial of OST-HER2 in the prevention or delay of recurrence in fully resected, pediatric lung metastatic osteosarcoma. The Company reiterates that additional data from its Phase 2b trial will be presented at the major osteosarcoma conference MIB Factor in Salt Lake City on Saturday June 28, 2025 at 3:30pm MDT. Concurrent with this announcement, the Company announced that it has submitted End of Phase 2 Meeting and Breakthrough Therapy Designation (BTD) requests to FDA based on the positive Type D Meeting feedback. The End of Phase 2 Meeting is expected to occur in the third quarter of 2025. This is in alignment with the company's overall regulatory strategy and timelines. "We are pleased with the feedback we received from the FDA regarding the use of external control comparators in settings where placebo-controlled randomization trials are not feasible – particularly in rare pediatric diseases such as the indication treated by OST-HER2 ," said Dr. Robert Petit, Chief Medical & Scientific Officer of OS Therapies. "Moreover, we received additional collaborative input regarding suggested statistical methods as we seek to compare OST-HER2 active treatment with external control arm(s) to support a Biologics Licensing Application (BLA) via the Accelerated Approval Program. Taken together, the feedback gives us insight on the FDA's current position and allows us to be fully prepared for the End of Phase 2 Meeting." OST-HER2 has received Rare Pediatric Disease Designation (RPDD) for osteosarcoma from the US FDA, and if it receives a conditional BLA via Accelerated Review prior to September 30, 2026, it will become eligible to receive a Priority Review Voucher (PRV) that it intends to immediately sell. The most recent PRV sale occurred in June 2025, valued at $160 million. The osteosarcoma treatment market was estimated at $1.2 billion in 2022 according to Data Bridge Market Research. Approximately 50% of patients are diagnosed with a lung metastasis at some point following surgical resection and chemotherapy. 3-year survival rates in patients who were not diagnosed with a metastasis are 59%. 3-year survival rates in patients who were diagnosed with pulmonary metastasis were 30%. The Company believes the market opportunity for OST-HER2 in the prevention of lung metastases is over $500 million. OST-HER2, an immunotherapy for osteosarcoma that uses a HER2-bioengineered form of the bacterium Listeria monocytogenes to trigger a strong immune response against HER2-expressing cancer cells, is featured in the movie Shelter Me: The Cancer Pioneers. The movie offers a look into canine comparative oncology, a field that compares treatment of cancers in dogs to those in people and covers developing treatments for rare forms of cancer. The movie is available via streaming on PBS' website. About OS Therapies OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the US Food & Drug Administration and Fast-Track and Orphan Drug designations from the US FDA and European Medicines Agency. The Company positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates submitting a Biologics Licensing Application (BLA) to the US FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma. In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit Forward-Looking Statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as "anticipate," "expect," "intend," "may," "will," "should" or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. OS Therapies cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to the approval of OST-HER2 by the US FDA and other risks and uncertainties described in "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's most recent Annual Report on Form 10-K and other subsequent documents the Company files with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. View source version on Contacts OS Therapies Contact Information: Jack Doll410-297-7793Irpr@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
